From September 1st, a large number of medical insurance will no longer be reimbursed

According to the documents of the State Administration of Health Insurance, the Interim Measures for the Administration of Drug Use in Basic Medical Insurance (hereinafter referred to as the Measures) will come into effect on September 1, 2020.
, it should be noted that the Basic Medical Insurance Drug Catalog, as formulated in the Measures, states that eight categories of medicines may not be included in the catalogue.
Specifically: preventive vaccines; tonic drugs; health drugs; hair loss, beauty weight loss and other enhanced functional drugs; drugs that cannot be charged separately for reasons such as inclusion in medical treatment programs; and medicines containing national precious and endangered wildlife herbs.
can not be included in the catalog, in fact, means that these eight types of medical insurance will not be reimbursed, the simple understanding is that retail pharmacies can not use health insurance card credit card sales.
fact, health insurance is one of china's basic social insurance policies, and health insurance reimbursement is also one of the things that we are very concerned about.
in addition to the above 8 types of drugs should not be included in the medical insurance directory, in fact, in recent years can be clearly found that all over the country there are drugs in the transfer of health insurance.
As of mid-June this year, jiangxi, Shandong, Beijing, Hunan, Sichuan, Guangdong, Tianjin, Zhejiang, Anhui, Guangxi and other at least 15 provinces and cities on the local health insurance catalog of additional varieties to remove a clear text, four provinces and cities to local health insurance supplement varieties to give a specific directory or guidance, and many provinces and cities have published the transfer list.
To this end, the industry believes that, with the deepening of China's basic medical insurance system reform, as China's large buyer and payer of health care, the National Health Insurance Bureau, is accelerating the medical insurance funds cage for birds, for the medical insurance drug restructuring to open up space.
fact, this is evident from the fact that Medicare drugs are making rapid progress.
E.e. in the context of a large number of drugs transferred out of health insurance, some time ago, the State Health Insurance Administration announced the "2020 National Health Insurance Drug Catalog Adjustment Work Programme", clearly proposed that the treatment of respiratory diseases related to the outbreak of drugs, clinically urgently needed innovative drugs, etc. into the scope of the declaration.
addition, in the evaluation process, this adjustment is also the first implementation of enterprise self-declaration.
of this year, out-of-catalog drug access will be subject to a declaration system, by enterprises in accordance with the requirements of the submission of declaration information, after examination and compliance with the reporting conditions into the scope of evaluation.
also proves that while the country is expanding the scope of medicare drugs, it is also releasing signals encouraging innovation in terms of scope of review, which fully demonstrates a clear direction in support of the development of innovative drugs.
In general, with the continuous promotion of volume procurement and adjustment of the medical insurance catalogue, the payment space for generic drugs and drugs with low clinical value is compressed, the payment of innovative drugs and clinically essential drugs is improved, and the pharmaceutical industry will accelerate the "cage-for-bird" and the upgrading of industrial structure will be further accelerated.